employer coverage glp-1 news october 2025 What You Need to Know About Employer Coverage for Weight-Loss Drugs

Both hexarelin and ipamorelin are synthetic growth hormone secretagogues (GHS) that act as agonists at the ghrelin receptor, formally GHSR-1a (growth hormone secretagogue receptor type 1a)

Quick and Comfortable: AquaGold procedures are typically quick, and the microinjection process is generally well-tolerated

Over a twelve-month period, this adds $130 to your total medication expense

The recent phase 2 trial of tirzepatide in patients with MASH provides support for the therapeutic potential of GIPpathway modulation in cardiometabolic disease and demonstrates how GIP signaling, when cotargeted with GLP-1RA, may contribute to weight loss, improved metabolic outcomes, and possibly cardiovascular protection ( However, these benefits are accompanied by concerns about side effects, cost, long-term sustainability and, above all, the loss of lean mass, which may be mitigated by concurrent exercise ( Exercise and lifestyle interventions remain foundational for obesity and metabolic disease management, offering broad health benefits, but are often limited by adherence and modest long-term weight loss ( Recent randomized controlled trials and meta-analyses suggest that combining GLP-1RAs with exercise may yield additive or synergistic effects on weight loss and metabolic syndrome severity as well as on oxidative stress and inflammation

Bodybuilders using IGF-1 supplements or injections should monitor for side effects such as joint pain, swelling in the hands and feet, fluid retention, muscle cramps, and numbness or tingling in extremities